Skip to content
MarketScale
‹ Back to IndustriesSciences

Intermittent Fasting: Understanding the Science Behind the Health Phenomenon

Amidst the ever-evolving landscape of health and nutrition, intermittent fasting emerges as a promising contender, with a growing body of research striving to uncover its full potential and implications. A recent surge of research has illuminated the potential benefits of this time-restricted eating pattern, making it more than just a passing trend. But what do…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Health BenefitsIntermittent FastingNutritionNutrition Science
Share

Key takeaways

01

Amidst the ever-evolving landscape of health and nutrition, intermittent fasting emerges as a promising contender, with a growing body of research striving to uncover its full potential and implications.

02

A recent surge of research has illuminated the potential benefits of this time-restricted eating pattern, making it more than just a passing trend.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Amidst the ever-evolving landscape of health and nutrition, intermittent fasting emerges as a promising contender, with a growing body of research striving to uncover its full potential and implications. A recent surge of research has illuminated the potential benefits of this time-restricted eating pattern, making it more than just a passing trend. But what do the studies really say?

Intermittent fasting in its most basic form involves going without food for a specific period, often ranging from 16 to 24 hours. Studies have shown that this eating pattern may lead to various health benefits, including improved heart health, better blood sugar regulation, and even increased lifespan. With a plethora of health benefits, some researchers, like Johns Hopkins Medicine neuroscientist Mark Mattson, Ph.D, suggest that intermittent fasting could even become part of standard medical advice alongside healthy diets and exercise.

However, it’s important to note that not all intermittent fasting methods are created equal. For example, the 5:2 fasting approach, which involves eating normally for five days and restricting calories for two, might be more effective than simply shortening your daily eating window. 

Is intermittent fasting the game-changer diet we’ve been waiting for in the realm of health and wellness? Or, does the science behind this wellness trend reveal a more nuanced understanding of its true benefits to bodily health? Joanna Chodorowska, holistic sports nutritionist and owner of Nutrition in Motion LLC, asserts that for intermittent fasting to truly be effective, it is essential to consider other crucial factors, such as proper nutrition.

Joanna’s Thoughts:

“Hi, I’m Joanna Chodorowska, a whole body health nutritionist, and I recently read the Women’s Day article about intermittent fasting, which provided five points on how intermittent fasting can improve your health. The one that resonated with me the most is point number four, where Dr Jason Fung mentioned intermittent fasting on its own can improve factors like insulin regulation, but if you’re eating highly processed, very high-calorie foods with little nutritional benefit, you’re not going to see many improvements from simply changing your eating window. And I would agree with that.

My viewpoint is that intermittent fasting alone is not the panacea for improving diabetes, cardiovascular function or antioxidant function; you have to eat real food, you have to balance the blood sugar, you have to include anti-inflammatory foods, eat antioxidant-rich foods and move your body to get the full benefits of intermittent fasting.

Just fasting alone will not do all that the article suggests. It can increase the benefits, but only if you include a balanced nutrition program that includes real food and exercise along with the intermittent fasting window, especially as you get older, over 50.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's 2024 report, covered by TechTarget in April 2024, estimated that a top-10 biopharma company could capture $5-7 billion in peak AI value over five years, with about 90% concentrated in R&D, manufacturing/supply chain, and commercial functions. McKinsey reported in November 2025 that despite rising AI investment, pharma companies have not yet seen shorter development timelines or better clinical success rates.

  • 01Deloitte estimates $5–7B peak AI value for top-10 biopharma firms over five years, with cost reductions appearing in 1–2 quarters and revenue gains taking 3–4 quarters.
  • 02McKinsey found pharma companies have not yet achieved shorter drug development timelines or improved preclinical and clinical success rates despite increased AI spending.
  • 03AI systems used in manufacturing, supply chain, and R&D functions may require validation under existing regulated systems frameworks like GAMP.

Sep 13, 2026

CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech, part of PSG and Dover, announced on May 27, 2026 that it is collaborating with Multiply Labs to develop an aseptic connector designed for robotic operation. The companies said the connector combines CPC's MicroCNX Nano Series with a proprietary interface engineered for robotic grippers, giving robots a consistent contact point during aseptic fluid transfers in Multiply Labs' closed cell and gene therapy processing systems.

  • 01Robotic grippers can reliably handle rigid parts but struggle with soft materials like bags and tubing, driving demand for robot-compatible connectors in sterile processing.
  • 02Commercial cell therapy production was under 5,000 doses per year in 2023 while global demand was estimated in the millions, creating manufacturing constraints.
  • 03Cell therapy manufacturing may involve upwards of 40 process steps, and optimal workflows remain under development without industrywide standardization.

Sep 10, 2026

Lab automation ROI hinges on integration, not instrument sensitivity claims

Lab automation ROI hinges on integration, not instrument sensitivity claims

At ADLM 2026, Waters and LabCollector delivered a clear message for lab leaders: the limiting factor in automation is often integration, not hardware. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer and is positioning it at “5x greater sensitivity” versus in-class instruments, according to SelectScience, but that advantage only carries through if sample prep, calibration and QA, middleware rules, and LIMS result review can keep pace. In parallel, LabCollector announced an AI Co-Scientist feature set for natural-language search, knowledge retrieval, and AI-assisted content creation inside ELN and LIMS workflows, also reported by SelectScience, shifting attention from pipetting speed to retrieval, approval, permissions, and versioning in systems that sit on the documentation path. The Scientist’s overview of semi-automated versus fully automated approaches reinforces the point: labs can automate in modules, but they have to run automation as one system.

  • 01The bottleneck in automation is often the handoff, instrument to middleware to LIMS, so sensitivity and throughput gains depend on interfaces and downstream review as much as the instrument spec.
  • 02Waters’ “5x greater sensitivity” positioning and LabCollector’s AI Co-Scientist both point to integration work, sample prep, calibration and QA, middleware rules, and LIMS result review, as the gating factor for ROI.
  • 03As ELN/LIMS add conversational search and AI-assisted content creation, speed gains move from pipetting to retrieval, approval, permissions, and versioning inside systems that sit in regulated or audited workflows.

Sep 3, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512